10-Q: NeurAxis Reports Increased Revenue but Widening Losses in Q1 2025

NeurAxis, Inc. reports a revenue increase of 38.5% year-over-year for Q1 2025, but also a widening net loss due to increased expenses.

Summary

• NeurAxis, Inc., a growth-stage company focused on neuromodulation therapies, reported its financial results for the first quarter of 2025.
• Net sales increased by 38.5% to $895,655, compared to $646,635 in Q1 2024, driven by volume growth from customers with full insurance reimbursement and those in financial assistance programs.
• Despite the revenue increase, the company's net loss widened to $2,278,684, compared to $2,120,651 in the same period last year.
• The operating loss also increased by 25.3% to $2,295,098, primarily due to higher general and administrative expenses, including costs related to new incentive plans and the settlement of a lawsuit.
• The company's gross margin decreased from 88.4% to 84.4% due to higher growth in discounted financial assistance programs and increased device manufacturing and shipping costs.
• Research and development expenses saw a significant increase of 987.2% to $60,556, driven by spending on a medical research project and the development of the RED device.
• As of March 31, 2025, NeurAxis had cash and cash equivalents of $2,005,370 and a working capital surplus of $439,823.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• Management is focused on securing widespread insurance coverage for the IB-Stim device and obtaining FDA clearance for other indications to drive future revenue growth.
• The company settled a lawsuit for $750,000, payable in monthly installments starting in January 2026.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased, losses widened and there are concerns about the company's ability to continue as a going concern. The settlement of a lawsuit adds further financial strain. The sentiment is cautiously negative.

Positives

• Net sales increased by 38.5%, indicating growing market adoption of the IB-Stim device.
• Other expense, net improved by 105.7% due to the absence of financing charges and the conversion of convertible notes.
• Research and development expenses increased significantly, indicating investment in future growth opportunities.
• The company is focused on securing widespread insurance coverage for its products, which could drive future revenue growth.

Negatives

• The net loss widened to $2,278,684, indicating ongoing challenges with profitability.
• The operating loss increased by 25.3%, driven by higher general and administrative expenses.
• The gross margin decreased from 88.4% to 84.4%, indicating increased costs or pricing pressures.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern, raising concerns about its long-term viability.
• The company settled a lawsuit for $750,000, which will require future cash outflows.

Risks

• The company's ability to continue as a going concern is dependent on generating sufficient revenues and raising additional funds.
• The company faces challenges in securing widespread insurance coverage for its products.
• The company's financial performance is subject to risks related to developing, manufacturing, and marketing its technologies.
• The company's internal controls over financial reporting have material weaknesses, which could affect the accuracy of its financial statements.
• The company is involved in legal proceedings, which could result in significant costs and liabilities.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it continues to pursue widespread insurance coverage of its IB-Stim device and seek FDA clearance of its device for other indications, as well as fund sales and marketing efforts to expand the adoption of RED.

Management Comments

• Management is focused on securing widespread insurance coverage for the IB-Stim device and obtaining FDA clearance for other indications to drive future revenue growth.

Industry Context

The company operates in the neuromodulation therapy market, which is experiencing growth due to increasing demand for non-pharmacological treatments for chronic conditions. The company's focus on pediatric applications differentiates it from some competitors, but it also faces challenges in securing insurance coverage and regulatory approvals.

Comparison to Industry Standards

• It is difficult to compare NeurAxis directly to industry standards due to its specific focus on pediatric neuromodulation and its stage as a growth company.
• Comparable companies in the neuromodulation space, such as Nevro Corp. and Boston Scientific, have significantly higher revenue and market capitalization, but they also operate in different therapeutic areas and have a broader product portfolio.
• The company's gross margin of 84.4% is relatively high compared to some medical device companies, but its operating expenses are also high, resulting in significant operating losses.
• The company's reliance on securing insurance coverage for its products is a common challenge in the medical device industry, and its success in this area will be critical to its future growth.

Legal Proceedings

• The company settled a lawsuit for $750,000, payable in monthly installments beginning in January 2026.
• Dr. Arturo Taca served notice to the Company that asserted an interest in its U.S. Patent No. 10,413,719 valued at $2,000,000 based on his own work in neurostimulation.

Related Party Transactions

• The company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016.
• The Company was granted an exclusive, worldwide non-transferable, royalty-free license for the auricular portion of certain patents owned by a limited liability company in which the Company's President and Chief Executive Officer and Chief Regulatory, Compliance and Privacy Officer both maintain an ownership interest.
• From time to time, a member of the Company's Board of Directors purchases IB-STIM devices from the Company at cost to conduct research and development activities.
• The Company's former Chief Financial Officer is contracted for services through a third-party public accounting firm.

Stakeholder Impact

• Shareholders face increased risk due to the company's widening losses and concerns about its ability to continue as a going concern.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers may be affected by potential changes in product availability or pricing if the company faces financial difficulties.
• Suppliers and creditors face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company plans to continue pursuing widespread insurance coverage for its IB-Stim device.
• The company plans to seek FDA clearance for its device for other indications.
• The company plans to fund sales and marketing efforts to expand the adoption of RED.
• The company plans to implement remediation steps to address material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

NeurAxis, IB-Stim, Financial Results, Neuromodulation, Revenue, Net Loss, Operating Loss, Q1 2025, RED Device, Insurance Coverage